Dulanermin
Also known as: AMG 951, Apo2L, PRO1762, recombinant human TRAIL, rhApo2L/TRAIL, rhTRAIL
Source Dulanermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human TRAIL (TNF‑related apoptosis‑inducing ligand) developed as an anticancer biologic; induces selective apoptosis of malignant cells while sparing most normal tissues.
Mechanism of Action
Activates death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), triggering caspase‑8 dependent apoptosis in tumor cells
Routes of Administration
Goals & Uses
- Colorectal cancer treatmentOncologyModerate
- Non-small cell lung cancer treatmentOncologyModerate
- Synergistic combination with chemotherapyOncologyModerate
- Apoptosis induction in tumor cellsAnticancerModerate
- Combination therapy with chemotherapyOncologyModerate
- Selective cancer cell killingTargeted TherapyModerate
- Solid tumor cytoreductionOncologyModerate
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Active severe infectionInfectiousModerate
- Hepatic impairmentOrgan DysfunctionHigh
- Severe uncontrolled infectionInfectionModerate
Adverse Effects
- Hepatotoxicity / elevated liver enzymesHepaticUncommon
- ThrombocytopeniaHematologicUncommonLow platelet count
- Infusion‑related reactions (fever, chills, hypotension)GeneralCommon
- Elevated liver enzymes (ALT/AST)HepaticUncommon
- Nausea and vomitingGastrointestinalCommon
- FatigueGeneralCommonLow energy or tiredness
- Cytopenias (neutropenia, thrombocytopenia)HematologicRare
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- BevacizumabLow
- Chemotherapeutic agents (e.g., gemcitabine, 5‑FU)Moderate
- FOLFOXLow
- Carboplatin/PaclitaxelLow
- CorticosteroidsLow
Population Constraints
- Pediatric patientsAgeRelative
- Patients with pre-existing hepatic diseaseOrgan DysfunctionRelative
- Pregnant or breastfeeding womenReproductiveRelative
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization only.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalNot licensed; used under Clinical Trial Authorisation.
Never received marketing approval; evaluated in Phase I–III trials for solid tumours and hematologic malignancies.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Dulanermin?
Recombinant human TRAIL (TNF‑related apoptosis‑inducing ligand) developed as an anticancer biologic; induces selective apoptosis of malignant cells while sparing most normal tissues.
What is Dulanermin used for?
Dulanermin is educationally associated with: Colorectal cancer treatment, Non-small cell lung cancer treatment, Synergistic combination with chemotherapy, Apoptosis induction in tumor cells, Combination therapy with chemotherapy, Selective cancer cell killing, Solid tumor cytoreduction. Educational only — not medical advice.
How is Dulanermin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Dulanermin?
Reported adverse effects include: Hepatotoxicity / elevated liver enzymes, Thrombocytopenia, Infusion‑related reactions (fever, chills, hypotension), Elevated liver enzymes (ALT/AST), Nausea and vomiting, Fatigue, Cytopenias (neutropenia, thrombocytopenia), Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dulanermin?
Recorded contraindications: Pregnancy, Active severe infection, Hepatic impairment, Severe uncontrolled infection. Consult a qualified clinician before use.